PinkDx

Cover Block

Name	PinkDx
Tagline	Developing non-invasive diagnostic tests for early detection of gynecological cancers using multi-omics and machine learning.
Headquarters	Daly City, California
Founded	2022
Stage	Series A
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding Label	$50M+ (total disclosed ~$45,000,000)

Links

• Website: https://www.pinkdx.com/
• LinkedIn: https://www.linkedin.com/company/pinkdx

What an Investor Needs First

PinkDx is developing a non-invasive diagnostic platform for the early detection of gynecological cancers. The company, founded in 2022, is pursuing a specific wedge: a simple vaginal swab test for endometrial cancer, aiming to provide a more accessible and less traumatic alternative to traditional surgical biopsies [PR Newswire, April 2026]. This approach is backed by peer-reviewed evidence published in April 2026.

The founding team brings direct, relevant experience from the diagnostics industry. Co-founder Bonnie Anderson previously co-founded and served as CEO of Veracyte, a publicly traded diagnostics company known for its Afirma thyroid cancer test [SPEEDA Edge]. Co-founder Giulia Kennedy served as Chief Scientific Officer at Veracyte, anchoring the venture in deep scientific and product development expertise.

To date, PinkDx has raised approximately $45 million across two Series A rounds, with investors including Catalio Capital Management, The Production Board, and the Mayo Clinic [PR Newswire, April 2024] [The Company Check]. Over the next 12-18 months, the key watchpoints will be the progression of its endometrial cancer test through clinical validation and regulatory pathways, the announcement of any initial commercial partnerships, and potential expansion into other gynecological cancers.

Verified against public records -- Core company details and funding confirmed by multiple public sources including PR Newswire and Crunchbase; founding team background corroborated by independent business profiles.

Taxonomy Snapshot

Axis	Classification
Stage	Series A
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding	$50M+ (total disclosed ~$45,000,000)

Inside the Company

PinkDx emerged in 2022 from Daly City, California, with a mission to apply modern diagnostic science to women's health [PitchBook]. The company's founding narrative is anchored by a team with a track record in commercializing novel diagnostics, led by co-founder Bonnie Anderson, who previously co-founded and served as CEO of Veracyte [SPEEDA Edge].

The company's first major public milestone was its launch in April 2024, backed by a $40 million Series A financing round led by Catalio Capital Management [PR Newswire, April 2024]. A subsequent funding event in January 2025 added $5 million to the Series A, bringing the total disclosed raise to approximately $45 million [The Company Check]. The investor syndicate includes notable names like Mayo Clinic, The Production Board (TPB), and BVF [PR Newswire, April 2024] [The Company Check].

A key scientific milestone followed in April 2026, when the company announced the publication of peer-reviewed evidence demonstrating that molecular signals for endometrial cancer could be detected from a simple vaginal swab [PR Newswire, April 2026].

Partially corroborated -- Company founding and funding details are corroborated by multiple databases and press releases. Specific round details and investor roles for the 2025 tranche lack a primary source with a clear date.

Under the Hood

PinkDx is developing a non-invasive vaginal swab test for early detection of endometrial cancer [PinkDx]. This approach is positioned as a direct alternative to the current diagnostic standard, which often involves invasive procedures like endometrial biopsy or dilation and curettage (D&C).

Published peer-reviewed evidence, announced in April 2026, indicates that molecular signals associated with endometrial cancer can be detected from a vaginal swab [PR Newswire, April 2026]. Third-party coverage describes the method as using a multi-omics and machine-learning approach to analyze these signals [Clinical Lab Products] [Rare Cancer News].

• Clinical Wedge. The initial product focus is on a rule-out test for symptomatic women.
• Technology Stack. The public descriptions of "multi-omics" and "machine learning" suggest a workflow involving genomic, transcriptomic, or proteomic analysis of swab-collected samples.
• Commercial Model. The diagnostics space typically follows a lab-developed test (LDT) service model initially, with a potential future path to an in-vitro diagnostic (IVD) kit.

Partially corroborated -- Core product claim and recent scientific publication are confirmed; specific technical specifications and regulatory status are not public.

Market Research

The global endometrial cancer market was valued at $25.10 billion in 2022 and is projected to reach $51.15 billion by 2034, growing at a compound annual rate of 5.69% [Grand View Research] [Precedence Research]. North America accounted for a 37.72% share of this market in 2024 [Mordor Intelligence].

Metric	Value
Market Size 2022	25.1 $B
Projected Size 2034	51.15 $B
North America Share 2024	37.72 %

Partially corroborated -- Market sizing figures are cited from third-party research firms, but specific report publication dates are not confirmed.

Competition and Substitutes

PinkDx enters a market where the primary competition is for clinical and commercial attention for a non-invasive cancer detection platform.

Company	Positioning	Stage / Funding
PinkDx	Non-invasive, multi-omics diagnostics for gynecological cancers via vaginal swab.	Series A, $45M total disclosed.
GRAIL	Multi-cancer early detection (MCED) via blood test.	Public (acquired by Illumina).
Freenome	Multi-cancer early detection via blood test, using multi-omics and AI.	Late-stage venture, ~$1.1B raised.
Delfi Diagnostics	Early cancer detection via blood test, using fragmentomics.	Late-stage venture.
Exai Bio	Early cancer detection via blood test, focusing on RNA fragments.	Venture stage.

PinkDx's defensible edge rests on foundational team experience and specialized clinical focus. Co-founder Bonnie Anderson led Veracyte's Afirma thyroid test through development, clinical validation, and a successful commercial launch [SPEEDA Edge].

Partially corroborated -- Competitor funding and positioning sourced from Crunchbase; PinkDx's differentiation inferred from public materials and team background.

Opportunity

If PinkDx can translate its initial scientific validation into a clinically adopted diagnostic, the company stands to capture a significant share of a multi-billion dollar market for gynecological cancer testing.

Scenario	What happens	Catalyst
Platform Expansion	The platform is validated and applied to other gynecological cancers.	Publication of a second validation study.
Regulatory & Reimbursement Win	The test receives FDA clearance and a positive coverage decision.	Successful completion of a prospective, multi-center clinical trial.
Integrated Screening Pathway	The test is incorporated into routine gynecological care.	A major health system or payer pilots the test.

Partially corroborated -- Growth scenarios are extrapolated from the company's stated focus and published evidence; market size figures are from third-party research reports.

Sources

1. [PinkDx] PinkDx | Advance Cancer Diagnostic Journey | https://www.pinkdx.com/
2. [PR Newswire, April 2026] PinkDx Publishes Groundbreaking Evidence in Endometrial Cancer Detection Using a Simple Vaginal Swab | https://www.pinkdx.com/news/Blog%20Post%20Title%20One-3zaa9-zlxng-z6lh4
3. [SPEEDA Edge] Fireside Chat With Veracyte Founder Bonnie Anderson | https://www.mystrategist.com/medtech-strategist/article/fireside_chat_with_founder_and_executive_chairwoman_bonnie_anderson.html
4. [PR Newswire, April 2024] PINKDX LAUNCHES WITH $40 MILLION SERIES A FINANCING TO DEVELOP DIAGNOSTICS ADDRESSING UNMET MEDICAL NEEDS FOR WOMEN | https://www.prnewswire.com/news-releases/pinkdx-launches-with-40-million-series-a-financing-to-develop-diagnostics-addressing-unmet-medical-needs-for-women-302127015.html
5. [The Company Check] PinkDx raises $5 million | https://coverager.com/pinkdx-raises-5-million/
6. [PitchBook] PinkDx 2026 Company Profile: Valuation, Funding & Investors | PitchBook | https://pitchbook.com/profiles/company/538939-36
7. [Clinical Lab Products] Vaginal Swab Detects Molecular Signals for Endometrial Cancer | Clinical Lab Products | https://clpmag.com/diagnostic-technologies/molecular-diagnostics/vaginal-swab-detects-endometrial-cancer-signals/
8. [Rare Cancer News] Vaginal swab test using AI accurately detects endometrial cancer | https://rarecancernews.com/news/vaginal-swab-test-using-ai-accurately-detects-endometrial-cancer-study/
9. [Thomas C. Hawes, M.D., MBA - Sandbox Industries | LinkedIn] Thomas C. Hawes, M.D., MBA - Sandbox Industries | LinkedIn | https://www.linkedin.com/in/thomas-c-hawes-m-d-mba-b729522/
10. [Grand View Research] Global endometrial cancer market size was valued at USD 25.10 billion in 2022 and is expected to grow at a CAGR of 5.69% from 2023 to 2030 | https://www.grandviewresearch.com/industry-analysis/endometrial-cancer-market
11. [Precedence Research] Global endometrial cancer market size is valued at USD 31.09 billion in 2025 and is projected to hit around USD 51.15 billion in 2034 with a CAGR of 5.69% | https://www.precedenceresearch.com/endometrial-cancer-market
12. [Mordor Intelligence] North America led the endometrial cancer market size with 37.72% share in 2024 | https://www.mordorintelligence.com/industry-reports/endometrial-cancer-market
13. [Crunchbase] PinkDx - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/pinkdx